Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 10/20 | 0.45 |
| ▸ | ITGB1 | P05556 | 2/20 | 0.38 |
| ▸ | ITGA4 | P13612 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | PPARG | P37231 | 1/20 | 0.35 |
| ▸ | PPARA | Q07869 | 1/20 | 0.35 |
| ▸ | LDHA | P00338 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL446627 | 0.86 | MME (0.39) | MMENPC1EPHX1 | |
| SCHEMBL21061397 | 0.81 | ADRB2 (0.41) | MMEITGB1ITGA4 | |
| SCHEMBL446219 | 0.81 | FPR2 (0.39) | MMESMN1; SMN2EPHX1MAPK1 | |
| SCHEMBL444879 | 0.72 | MAPK1 (0.56) | MMENPC1HPGDSMN1; SMN2MAPK1 | |
| SCHEMBL28841070 | 0.71 | MME (0.44) | MMEITGB1ITGA4NPC1HPGD | |
| SCHEMBL6523 | 0.70 | MME (0.40) | MMENPC1HPGDSMN1; SMN2EPHX1 | |
| SCHEMBL28840772 | 0.70 | MME (0.46) | MMEITGB1ITGA4NPC1HPGD | |
| SCHEMBL3044036 | 0.70 | GRIN2D (0.49) | MMENPC1HPGDSMN1; SMN2 | |
| SCHEMBL446074 | 0.69 | L3MBTL1 (0.38) | MMESMN1; SMN2MAPK1 | |
| SCHEMBL16040906 | 0.67 | ADRB2 (0.44) | MMENPC1HPGDSMN1; SMN2MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120065195-A1 | COMPOUNDS FOR TREATING NEURODEGENERATIVE DISEASES | ARRAY BIOPHARMA INC. | 2012-03-15 | — | — | US | disclosed |
| WO-2011123674-A1 | COMPOUNDS FOR TREATING NEURODEGENERATIVE DISEASES | ARRAY BIOPHARMA INC. (US) | 2011-10-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065195-A1 | COMPOUNDS FOR TREATING NEURODEGENERATIVE DISEASES | APP, BACE1, PSEN1 | MME 50/4885ITGB1 4417/4885ITGA4 4859/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.